Stockreport

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

Tvardi Therapeutics, Inc.  (TVRD) 
PDF Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline [Read more]